When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.
CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines’ pivotal pancreatic cancer study for the first time, he was rendered speechless, he …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits
Revolution Medicines starts shipping experimental pancreatic cancer drug
Pill offers hope in treating deadly pancreatic cancer
Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows
Scientifically Speaking: A pill takes on pancreatic cancer
Experimental drug shows promise against deadly pancreatic cancer
Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more
Promising new treatment for pancreatic cancer doubles survival rates
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically…
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for…
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy
